Sign In
Buy LTRN
$2.75
+0.140 (+5.36%)
At Close: Aug 04, 2026
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
08:21am, Wednesday, 11'th Aug 2021
DALLAS, Aug. 11, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q2 2021 Results - Earnings Call Transcript
06:43am, Saturday, 31'st Jul 2021
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q2 2021 Results - Earnings Call Transcript
DALLAS, July 27, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the
Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven
02:30am, Monday, 26'th Jul 2021
Press release
Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET
04:08pm, Thursday, 22'nd Jul 2021
DALLAS, July 22, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug
LTRN Stock Increases Over 10% Pre-Market: Why It Happened
08:24am, Tuesday, 20'th Jul 2021
The stock price of Lantern Pharma Inc. (NASDAQ: LTRN) increased by over 10% pre-market. This is why it happened.
Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models
08:12am, Tuesday, 20'th Jul 2021
Lantern Pharma Inc (NASDAQ: LTRN) has announced new preclinical data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center. These data d
Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
07:00am, Tuesday, 20'th Jul 2021
DALLAS, July 20, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform t
3 Little Known AI Stocks for the Future
01:00pm, Sunday, 18'th Jul 2021
With the global release of 5G connectivity, machine learning has become more of a secular trend than ever before.
Lantern Pharma: Drug Recycling With AI
12:12am, Tuesday, 08'th Jun 2021
Lantern Pharma: Drug Recycling With AI
Lantern Pharma - Using AI to Transform The Cost & Risk of Cancer Drug Development
08:14am, Tuesday, 25'th May 2021
Artificial intelligence is one of the most fascinating and powerful technological advances to come along over the past decade. The idea that we can use machine learning and data to make a positive imp
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q1 2021 Results - Earnings Call Transcript
01:45am, Tuesday, 04'th May 2021
Lantern Pharma Inc. (LTRN) CEO Panna Sharma on Q1 2021 Results - Earnings Call Transcript
Lantern Pharma Reports First Quarter 2021 Financial Results and Operational Highlights
04:32pm, Monday, 03'rd May 2021
DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform
DALLAS, May 3, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the c
Lantern Pharma's Proprietary A.I. Platform for Precision Oncology Drug Development, RADR®, Surpasses 4.6 Billion Datapoints, Accelerating the Company's Progress in the Development of Biopharma Collaborations and Partnerships and Advancing the Company's Strategy to Develop the World's Largest A.I.
07:00am, Thursday, 29'th Apr 2021
DALLAS, April 29, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug
